secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKWELL MEDICAL, INC. (RMTI)
CIK:        0001041024
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001628280-23-029166
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rockwell Medical acquires Evoqua concentrates, raises guidance, expects Q4 profitability
--------------------------------------------------------------------------------

- Q2 2023 net loss $3.3M ($0.18/sh) vs $5.0M loss ($0.43/sh) in Q2 2022; net sales $18.1M vs $18.7M prior year.
- Acquired Evoqua concentrates business for $12.2M; Evoqua generated $18M annual revenue and $3.3M annual EBITDA.
- Increased 2023 net sales guidance to $82-86M (from $78-82M) and gross profit guidance to $8-10M (from $7-9M).
- Expects to achieve profitability from operations in Q4 2023 and going forward.
- Pro forma cash $16.2M after $13.8M warrant exercise and acquisition funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1041024/000162828023029166/0001628280-23-029166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1041024/000162828023029166/rmti-20230814.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-029166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer